Jill Buck
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Jill Buck is Chief Development Officer at enGene Therapeutics, Inc. starting in 2025.
Formerly, Ms. Buck was EVP & GM Gene Therapy at Alaunos Therapeutics, Inc. Education includes an undergraduate degree from Boston College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-06-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ENGENE THERAPEUTICS INC. | Corporate Officer/Principal | 01-09-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
enGene Holdings, Inc.
enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau